Join us for a TIDES USA Investor Recap Call – May 22, 2025, at 8 am ET
Codexis was Founded in 2002 with the Goal of Engineering Exquisite Enzymes for a Variety of Industries and Applications
Today, we are a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing by leveraging our proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins.
We’ve engineered the enzymes that have enabled some of the biggest pharmaceutical products ever developed, including Januvia (sitagliptin), Lipitor (atorvastatin) and Paxlovid (nirmatrelvir). Our work has been recognized with multiple Green Chemistry Challenge Awards from the American Chemical Society and we are known for our platform’s proven ability to revolutionize enzyme performance by increasing activity, specificity, and stability. Building upon this legacy, today we are focused on applying our deep expertise to the enzymatic manufacturing of small interference ribonucleic acid (siRNA) therapeutics.
Enabling the Exponential Expansion of a New Class of Medicines
Similar to the growth seen with monoclonal antibodies, siRNA therapeutics are poised for exponential expansion over the coming decade with more than 450 biological compounds in clinical development. Today, the oligonucleotides for siRNA therapeutics are synthesized chemically, meaning the process utilizes metric tons of toxic waste that needs to be burned off, which leads to a massive carbon footprint for its producers.
Codexis is uniquely positioned to expand this development by providing enzymatically synthesized siRNA constructs. Our siRNA is manufactured in an aqueous (water-based) solution, which drives down cost and avoids heavy use of toxic solvents.
